Business Context and Reporting Period
This Form 8-K filing by Shuttle Pharmaceuticals Holdings, Inc. (SHPH) reports corporate governance changes effective September 12, 2025. The company is an emerging growth company incorporated in Delaware with its principal executive offices in Gaithersburg, MD.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.
Material Changes
The primary material change reported is the expansion of the Board of Directors and the reassignment of committee leadership:
- New Directors: Sachin Pathigoda and Angel Liriano were appointed as directors on September 12, 2025.
- Committee Appointments (Sept 15, 2025):
- Sachin Pathigoda: Chairman of the Nominating and Corporate Governance Committee; Member of the Audit Committee.
- Angel Liriano: Chairman of the Compensation Committee; Member of the Nominating and Corporate Governance Committee.
- George Scorsis: Appointed as Chairman of the Audit Committee.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies. The document confirms there are no family relationships between the new directors and existing officers, and no material interests in transactions requiring disclosure under Item 404(a) of Regulation S-K.
Key Facts for Investor Verification
- Verify the professional backgrounds and qualifications of new directors Sachin Pathigoda and Angel Liriano.
- Confirm the updated composition of the Audit, Compensation, and Nominating and Corporate Governance Committees.
- Note that Christopher Cooper is serving as Interim Chief Executive Officer as of the signing date (September 18, 2025).
- Check subsequent filings for financial data, as this 8-K contains no financial metrics.